Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Sndx-5613
2. 2169919-21-3
3. Lz0m43nnf2
4. Sndx5613
5. Sndx-5613 Free Base
6. N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-n-propan-2-ylbenzamide
7. Sndx50613
8. Benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-
9. Sndx-50613
10. Revumenib [inn]
11. Unii-lz0m43nnf2
12. Sndx5613 Free Base
13. Sndx50613 Free Base
14. Chembl4650827
15. Schembl19693219
16. Schembl19693428
17. Gtpl11882
18. Sndx-50613 Free Base
19. Ex-a4343
20. Nsc825775
21. S8996
22. Nsc-825775
23. Ac-36885
24. Hy-136175
25. Cs-0120274
26. N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-n-isopropylbenzamide
| Molecular Weight | 630.8 g/mol |
|---|---|
| Molecular Formula | C32H47FN6O4S |
| XLogP3 | 4.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 11 |
| Exact Mass | 630.33635334 g/mol |
| Monoisotopic Mass | 630.33635334 g/mol |
| Topological Polar Surface Area | 116 Ų |
| Heavy Atom Count | 44 |
| Formal Charge | 0 |
| Complexity | 1040 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
NDC API
NDC Package Code : 65392-3402
Start Marketing Date : 2023-11-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Revumenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Revumenib, including repackagers and relabelers. The FDA regulates Revumenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Revumenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Revumenib supplier is an individual or a company that provides Revumenib active pharmaceutical ingredient (API) or Revumenib finished formulations upon request. The Revumenib suppliers may include Revumenib API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Revumenib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Revumenib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Revumenib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Revumenib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Revumenib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Revumenib suppliers with NDC on PharmaCompass.
Revumenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Revumenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Revumenib GMP manufacturer or Revumenib GMP API supplier for your needs.
A Revumenib CoA (Certificate of Analysis) is a formal document that attests to Revumenib's compliance with Revumenib specifications and serves as a tool for batch-level quality control.
Revumenib CoA mostly includes findings from lab analyses of a specific batch. For each Revumenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Revumenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Revumenib EP), Revumenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Revumenib USP).
LOOKING FOR A SUPPLIER?
